Zeaxanthin is a carotenoid pigment concentrated in the macula of the eye — specifically the CENTRAL macula (the fovea), while lutein occupies the peripheral macula. Together they form the "macular pigment" that filters blue light and protects photoreceptors from oxidative damage. The AREDS2 trial (4,203 participants) confirmed that lutein + zeaxanthin supplementation reduced advanced AMD progression by 18% and REPLACED beta-carotene (which increased lung cancer in smokers) in the AREDS formula. Our research shows zeaxanthin is less bioavailable than lutein from dietary sources, making supplementation particularly valuable.
Zeaxanthin (3R,3'R-zeaxanthin in fovea; meso-zeaxanthin from lutein isomerization) has dual protective mechanisms: (1) Blue light filtration — zeaxanthin absorbs 430-500nm light (high-energy visible light that generates reactive oxygen species in photoreceptors), acting as an internal "blue light filter" before the light reaches the photoreceptor outer segments; (2) Antioxidant — quenches singlet oxygen and scavenges peroxyl radicals generated by photooxidation in the lipid-rich retinal environment; (3) membrane stabilization — integrates into photoreceptor outer segment membranes, reducing lipid peroxidation; (4) in the brain, zeaxanthin protects neuronal membranes from oxidative damage (same mechanism as in retina).
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.